AMS-17 

AMS-17 is a potent NLRP3 inhibitor, inhibiting microglia activation in vitro and in vivo. AMS-17 also inhibits cytokines such as caspase-1, TNF-α, IL-1β and inducible nitric oxide synthase (iNOS) in N9 cells. AMS-17 can be used for researching inflammation-associated neurological disorders, such as vascular dementia (VaD)^[1][2].

AMS-17 (20 mg/kg; i.p; for 5 days) improves cognitive function, enhanced blood-brain barrier (BBB) integrity, and promotes remyelination in VaD mice. AMS-17 reduces neurodegeneration and decreases the expression of NLRP3 and its associated proteins, Apoptosis-associated speck-like protein (ASC), and cleaved caspase-1 in the brain. AMS-17 also lowers pro-inflammatory TNF-α and IL-1β levels, while increasing the anti-inflammatory IL-4 level in the blood^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

386.35

C₁₅H₁₃F₃N₄O₃S

3019885-78-7

O=C1N(CCCN1S(=O)(C2=CC=C(C=C2)C(F)(F)F)=O)C3=CN=CN=C3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Zhang C, et al. Targeting NLRP3 signaling by a novel-designed sulfonylurea compound for inhibition of microglial inflammation. Bioorg Med Chem.  [Content Brief]

  [2]. Akif A, et al. Targeting NLRP3 signaling with a novel sulfonylurea compound for the treatment of vascular cognitive impairment and dementia. Fluids Barriers CNS. 2025 Jun 3;22(1):55.  [Content Brief]